FDA RF Microneedling Safety Communication: What It Says

The United States Food and Drug Administration's 15 October 2025 safety communication reports serious complications with certain uses of radiofrequency microneedling. It names five harms but provides no incidence data. It is not a UK alert, recall, withdrawal or ban. For buyers, it makes device clearance, operator training, consent and reporting material questions.

What the FDA safety communication says

The United States Food and Drug Administration safety communication dated 15 October 2025 concerns potential risks with certain uses of radiofrequency, or RF, microneedling. It states that serious complications have been reported with certain uses of RF microneedling devices. The agency names burns, scarring, fat loss, disfigurement and nerve damage. It adds that some reported cases needed medical intervention or surgical repair.

The communication describes RF microneedling as a medical procedure, not a cosmetic treatment. It says that RF microneedling devices should not be used at home. Its described uses are dermatologic and aesthetic skin procedures intended to improve the appearance of skin, including treatment of wrinkles and procedures described as resurfacing, tightening or rejuvenation.

The FDA says these devices are Class II medical devices cleared through the 510(k) process. It directs readers to its 510(k) database to check a particular device, including its authorised indications and clearance date. That is a document-checking instruction, not a finding that every device, setting, operator or use has the same risk profile.

For a reader assessing a procedure that combines an energy device with a topical material, this communication addresses the RF microneedling device half of the route. It does not assess the topical material, whether material enters through the treated skin, or the regulatory position of any substance applied after treatment. Those are separate questions. The communication is significant because the regulator sets out the named complications in its own safety notice, but its scope must be kept exact.

Five named harms, and what cannot be inferred

The five harms named by the FDA are burns, scarring, fat loss, disfigurement and nerve damage. A careful reading keeps those terms together with the source's wording: serious complications have been reported with certain uses. The communication does not provide a case total, the number of procedures performed, a reporting denominator, an incidence estimate or a frequency estimate.

That absence matters. A safety communication based on reported complications establishes that the events have occurred. It does not establish how likely an event is for a given person, device, treatment area, setting, depth, energy level or operator. It also does not allow a reader to compare frequency between RF microneedling and another procedure.

Fat loss deserves a separate question in consent discussions because it is not ordinarily framed in the same way as short-lived swelling or redness after a procedure. The FDA communication names fat loss among serious reported complications. It does not provide a recovery timetable, prognosis or estimate of reversibility. A provider's verbal description of expected temporary effects should therefore not displace a written discussion of the five harms identified in the communication.

Reader question	What the FDA communication supports	What it does not support
Have serious complications occurred?	Yes, with certain uses.	How frequently they occur.
Which harms are named?	Burns, scarring, fat loss, disfigurement and nerve damage.	A complete prognosis for each harm.
Do reports prove a risk rate?	No.	A numerical likelihood for an individual procedure.
Does the notice identify one device?	No manufacturer or device is named.	That every device has identical evidence or risk.

This is the practical decision rule: treat the communication as a reason to identify the exact device and planned procedure, not as a basis for calculating personal risk.

What the communication does not say

The limits of the document are as important as its warnings. The FDA gives no number of reports, no overall total and no incidence. It follows that no rate, percentage or statement of frequency can be taken from the communication. Reported cases describe that something has happened, not how often it happens.

The FDA says its evaluation is ongoing. The communication does not name a manufacturer or a device. It is not a recall, withdrawal or ban. It does not say that all RF microneedling procedures are unsafe, and it does not provide a comparative assessment of devices, practitioners, treatment settings or patient groups.

The notice does not use the phrase off label. Nor does it say whether the uses it describes fall inside any individual device's cleared indications. That distinction cannot be filled in by assumption. A 510(k) record can help establish what the FDA cleared a particular device for and when, but clearance information must still be read against the actual planned use.

The document also does not address products applied to skin after microneedling. It does not classify a topical product, assess a combined procedure, or determine whether a substance is appropriate for use on disrupted skin. A reader considering that separate issue should keep the device question and the post-procedure topical question apart. Combining them under a broad label such as regenerative treatment can obscure which product, device, route and claim is actually being assessed.

Reported complications are a safety signal. They are not a frequency calculation, a device-specific verdict or a UK legal determination.

What a buyer or procedure candidate should check

The FDA recommendations to patients provide a short starting point. Be aware of the reported complications. Discuss the benefits and risks of all available skin procedures with a health care provider. Seek care from a licensed provider with training and experience on these devices. Ask which device is planned. Seek licensed care for a problem after a procedure, and report problems to the FDA through MedWatch.

Those points can be converted into a record-checking sequence before a procedure is booked or a device is procured. Ask for the exact device name and model, then check the relevant FDA 510(k) entry for its authorised indications and clearance date. Ask who will operate the device, who supervises if applicable, and what training that person has on that device. Training should be device-specific enough to answer questions about planned settings and treatment depth.

Ask what settings and depth are planned for the particular area and why. This does not require a reader to prescribe a setting. It requires the operator to explain the intended procedure rather than relying on a generic description of RF microneedling. Read the consent form before treatment and check whether it addresses burns, scarring, fat loss, disfigurement and nerve damage. Their absence is a question to raise.

Identify the exact device rather than accepting a procedure label alone.
Check the device's 510(k) record and authorised indications.
Establish who operates it and their training on that device.
Ask about planned depth and settings for the area concerned.
Check that consent addresses all five named harms.
Know where a complication should be reported in the relevant jurisdiction.

This is not treatment advice. It is a document and consent review process for a medical procedure whose risks are described by the FDA in the communication.

The United Kingdom position and reporting routes

No equivalent United Kingdom alert was found in a search conducted on 24 October 2026. That absence should be stated as an absence, not converted into a finding that the issue does not arise in the United Kingdom. The FDA communication has no legal force in the United Kingdom.

In the United Kingdom, these devices are medical devices overseen by the Medicines and Healthcare products Regulatory Agency, commonly called the MHRA. A problem with the device itself should be reported through the MHRA route. A problem with how a procedure was carried out should first be raised with the practitioner. Depending on the practitioner and their registration, a further route may be their professional regulator, or the Joint Council for Cosmetic Practitioners or Save Face where the practitioner is registered.

These routes deal with different matters. Device reporting concerns a possible issue involving the medical device. A complaint about professional conduct, competence, consent or delivery of a procedure may require a different route. A reader should preserve relevant records, including the device identity where known, the date, consent documents, photographs where appropriate, aftercare material and correspondence. The appropriate body can then decide whether the matter falls within its remit.

United States classification terminology should not be transplanted into UK law. The FDA's statement that RF microneedling devices are Class II medical devices cleared through 510(k) describes the United States framework. It does not determine UK classification, market status, professional scope or the legal status of a procedure in the United Kingdom.

For safety assessment, the useful cross-border lesson is narrower: identify the exact device, distinguish device issues from procedure issues, and avoid treating a foreign regulator's communication as if it were a domestic alert.

Professional-body response and the boundary of attribution

On 8 December 2025, the American Society for Laser Medicine and Surgery and the American Society for Dermatologic Surgery issued a joint response to the FDA safety communication. The two societies said that RF microneedling can be performed safely and effectively when used or supervised by an appropriately trained, board certified physician. They also said members should raise the reported safety issues with manufacturers before buying a device.

The societies further said that burns, scarring, fat loss, disfigurement and nerve damage belong in consent forms. This is a professional-body response, not wording from the FDA communication. The distinction matters because the FDA communication itself gives recommendations to patients and providers but does not make the societies' statement about board certification.

For a buyer, the response adds a procurement question: before acquiring a device, ask how the manufacturer addresses the reported safety issues. That enquiry is not a substitute for independent review of clearance information, instructions for use, training arrangements, maintenance records, reporting arrangements and the intended clinical governance process. Nor does a statement by professional societies establish that a particular procedure, operator or device is appropriate in a particular setting.

A sound file separates three categories of material: what the FDA has reported, what professional bodies have said in response, and what the supplier's own documents claim. Conflating them can make a supplier statement appear regulatory, or make an ongoing regulatory evaluation appear conclusive. A source label beside each claim is the simplest control.

Limits of this reference

This reference concerns the FDA safety communication of 15 October 2025 about certain uses of RF microneedling devices. It is not a clinical protocol, a personal risk assessment, a comparison of devices, a treatment recommendation or a review of any practitioner. It does not determine whether someone should have RF microneedling. That is a patient decision requiring discussion with an appropriately qualified health professional.

It does not assess exosome products, extracellular vesicles, other topical materials, injectable products or substances applied after microneedling. It also does not decide whether a combined device and topical procedure complies with United Kingdom rules. The route created by skin disruption and the status of a material applied afterwards are separate regulatory and product-assessment questions.

The communication does not supply the data needed to estimate incidence, compare risk between devices or infer a population rate. It cannot be used to say that any named device is implicated or that any unnamed device is free of the reported complications. It names no manufacturer and no device.

Regulatory positions, safety communications and reporting systems can change. Readers using this page for procurement, governance or consent review should check the current primary material from the relevant regulator and confirm the current status of the exact device under consideration. The central reading discipline remains stable: retain the source's wording, identify what it omits, and do not turn reported cases into a frequency claim.

Questions readers ask

Is the FDA RF microneedling communication a ban?

No. The FDA communication is not a recall, withdrawal or ban. It says serious complications have been reported with certain uses of RF microneedling devices and that its evaluation is ongoing. It does not name a manufacturer or a specific device, so it cannot be read as a device-specific prohibition.

Does the FDA communication say how common burns or fat loss are?

No. It gives no number of reports, procedure total, incidence or frequency. It names burns, scarring, fat loss, disfigurement and nerve damage as reported serious complications. Reports show that events have occurred, but they do not provide a rate for a procedure, device, setting or individual.

What should I look up in the FDA 510(k) database?

Identify the exact device first. The FDA says readers can use its 510(k) database to check a particular device, its authorised indications and its clearance date. A database entry should not be treated as a general assurance about every use, treatment setting, operator or combination with another product.

Does the FDA notice apply in the United Kingdom?

The FDA communication has no legal force in the United Kingdom. No equivalent UK alert was found in a search conducted on 24 October 2026. UK device matters fall under the MHRA framework, so a United States Class II and 510(k) description does not determine UK classification or legal status.

What should be in an RF microneedling consent discussion?

The FDA recommends discussing benefits and risks with a health care provider. Its communication names burns, scarring, fat loss, disfigurement and nerve damage. Ask which device will be used, who will operate it, what training they have on that device, and why the proposed settings and depth are planned.

Where should a UK problem with RF microneedling be reported?

A possible problem with the device itself should follow the MHRA reporting route. A concern about how a procedure was carried out should first be raised with the practitioner and may then fall to their professional regulator, or to the Joint Council for Cosmetic Practitioners or Save Face where they are registered.

Does this communication assess products applied after microneedling?

No. The FDA communication concerns certain uses of RF microneedling devices. It does not classify, assess or endorse a topical material applied after skin disruption. The device question and the question of a substance applied after microneedling should be assessed separately.